Prof. Jan S. Moreb

Email: morebjs@medicine.ufl.edu

Qualifications

Publications(Selected)

1. Moreb JS, Ucar D, Han S, Amory JK, Goldstein AS, Ostmark B, Chang LJ. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact 2012;195:52-60.
2. Duff JM, Moreb JS, Muwalla F. Severe neutropenia following a prolonged course of vancomycin that progressed to agranulocytosis with drug re-exposure. The Annals of Pharmacotherapy 2012; 46:e1.
3. Moreb JS, Salmasinia D, Hsu J, Hou W, Cline C, Rosenau E. Long-term outcome after autologous stem cell transplantation with adequate peripheral blood stem cell mobilization using plerixafor and G-CSF in poor mobilizer lymphoma and myeloma patients. Advances in Hematology 2011; 2011:517561.
4. Han S, Wang Y, Wang B, Patel E, Okada S, Yang L-J, Moreb JS, Chang L-J. Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells from hematopoietic stem cells. Journal of Immune Based Therapies and Vaccines 2010; 8:8.
5. Amory JK, Muller CH, Isoherranen N, Shimshoni J, Paik J, Moreb JS, Amory DW Sr., Evanoff R, Goldstein A, Griswold MD. Suppression of spermatogenesis by WIN 18,446 is mediated by inhibition of testicular retinoic acid biosynthesis. J Androl 2011; 32:111-119.
6. Katz J, Gong y, Salmasinia D, Hou W, Burkley B, Ferreira P, Casanova O, Langaee TY, Moreb JS. Genetic Polymorphisms Associated with Bisphosphonate induced Osteonecrosis of the Jaw (BONJ) – A Cohort Study. International Journal of Oral & Maxillofacial Surgery 2011; 40:605-611.
7. Salmasinia D, Wingard JR, Chang M, Moreb JS. Combination of IFN-á/GM-CSF as a maintenance therapy for multiple myeloma patients after autologous stem cell transplantation (ASCT): A prospective phase II study. Clinical Medicine Insights: Oncology 2010; 4:117–125
8. Navarro WH, Agovi M-A, Logan B, Bacigalupo A, Ballen K, Bolwell B, Frangoul H, Gupta V, Hahn T, Ho V, Juckett M, Lazarus HM, Litzow MR, Liesveld J, Moreb JS, Marks DI, McCarthy P, Pasquini MC, Rizzo JD. Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) in adults. Biol Blood Marrow Transplant 2010; 16:1442-1450.
9. Cable C, Buzzeo MP, Schold JD, Khan S, Leather H, Moreb J, Jamieson K, Scornik J, Amdur RJ, Wingard JR, Reddy V. Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT. Bone Marrow Transplant 2010; 45:31-37.
10. Subbiah S, O'Connell F, Kobraei KB, Ramos-Caro FA, Moreb JS. Unusual multiple myeloma cutaneous manifestation following nonmyeloablative allogeneic stem cell transplantation. Clin Adv Hematol Oncol 2009; 7:800-802.
11. Patel E, Wang B, Lien L, Yang L-J, Moreb JS, Chang L-J. Diverse T cell differentiation potentials of human fetal thymus, fetal liver, cord blood and adult bone marrow CD34 cells on lentiviral Delta-like 1-modified mouse stromal cells. Immunology 2009; 128 (1 suppl):e497-505.
12. Katz J, George T, Sandow P, Machado M, Dickerson L, Moreb JS. Bisphosphonate-induced osteonecrosis of the Jaw: Long-term outcomes. J support Oncol 2009; 7:9-10. (letter)
13. Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther 2008; 3:237-246. (Review)
14. Moreb JS, Baker HV, Chang LJ, Amaya M, Lopez MC, Ostmark B, Chou W. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer 2008; 7:87. [Had more than 1500 hits in 2 months of after publication]
15. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009; 178: 48-55. [Top 10 downloaded articles in 2009]Kumar S, Pérez WS, Zhang MJ, Ballen K, Bashey A, To LB, Bredeson CN, Cairo   MS, Elfenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JS, Pavlovsky S, Reece DE, Vesole DH, Wiernik PH, Hari P. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 2008; 14:1134-1140.
16. Han S, Wang B, Cotter MJ, Yang LJ, Zucali J, Moreb JS, Chang LJ. Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells. Mol Ther 2008; 16:269-279.
17. Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. High expression of ALDH1A1 and ALDH3A1 in lung adenocarcinoma seems part of the malignant transformation with increased expression in pneumocytes from cigarette smokers. Lung Cancer 2008; 59:340-349.
18. Liu H, Moreb JS. Association of multiple myeloma and inflammatory bowel diseases. Dig Dis Sci 2008; 53:863-864. (Letter)
19. Moreb JS, Zucali JR, Ostmark B, Benson NA. Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry-based assay. Cytometry B Clin Cytom 2007; 72:281-289
20. Moreb JS, Muhoczy D, Ostmark B, Zucali JR. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol 2007; 59:127-136.
21. Liu H, Yuan CM, Heinerich J, Braylan RC, Chang MN, Wingard JR, Moreb JS. Flow      Cytometric Disease Monitoring in Patients with Multiple Myeloma undergoing Autologous Stem Cell Transplantation: A Retrospective Study. Leuk Lymphoma 2008; 49:306-314.
22. Machado M**, Moreb JS, Khan S. Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation. Bone Marrow Transplantation 2007; 40:979-982.